The new week brings with it fresh attempts for several markets to hit new highs, with the FTSE 100 pushing around the 9,000 ...

GSK plc recently received approval from the U.S. Food and Drug Administration (FDA) for a prefilled syringe version of SHINGRIX, the company’s vaccine for shingles (herpes zoster). The ...

Xelix, a leading agentic AI software company in the Accounts Payable (AP) space, today announced a $160 million Series B ...

In July 2025, Inovio Pharmaceuticals conducted a Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy ...

The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly ...

The Global Bladder Cancer Market was valued at USD 4.4 Billion in 2024, and it is expected to reach USD 7.2 Billion by 2035, ...

The Cancer Immunotherapy market, valued at USD 220.94 billion in 2024, is expected to register robust revenue CAGR of 13.6%. Re ...

This under-the-radar growth stock in the FTSE 250 index just jumped to a 52-week high. Can it keep climbing higher from here?

Xelix has raised $160m in a Series B to accelerate AI-driven innovation in accounts payable and expand globally.